VRCD.F Stock Overview
Develops prognostic and diagnostic tests for kidney transplant patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Verici Dx plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.03 |
| 52 Week High | UK£0.12 |
| 52 Week Low | UK£0.03 |
| Beta | 1.82 |
| 11 Month Change | -53.85% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| VRCD.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.7% | 0.3% |
| 1Y | n/a | 15.2% | 31.1% |
Return vs Industry: Insufficient data to determine how VRCD.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how VRCD.F performed against the US Market.
Price Volatility
| VRCD.F volatility | |
|---|---|
| VRCD.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VRCD.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine VRCD.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 19 | Sara Barrington | www.vericidx.com |
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure.
Verici Dx plc Fundamentals Summary
| VRCD.F fundamental statistics | |
|---|---|
| Market cap | US$10.24m |
| Earnings (TTM) | -US$4.81m |
| Revenue (TTM) | US$4.33m |
2.4x
P/S Ratio-2.1x
P/E RatioIs VRCD.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRCD.F income statement (TTM) | |
|---|---|
| Revenue | US$4.33m |
| Cost of Revenue | -US$3.00k |
| Gross Profit | US$4.34m |
| Other Expenses | US$9.15m |
| Earnings | -US$4.81m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 100.07% |
| Net Profit Margin | -110.99% |
| Debt/Equity Ratio | 0% |
How did VRCD.F perform over the long term?
See historical performance and comparison